natgillin/translations-raw huggingface dataset:
træthed, svimmelhed, søvnighed, opkastning, diarré, kvalme, fordøjelsesbesvær og forhøjet indhold af leverenzymer i blodet. ikke almindelige (forekommer hos mellem 1 og 10 ud af 1.000 patienter): udslæt, hårtab. sjældne (forekommer hos mellem 1 og 10 ud af 10.000 patienter): alvorlig allergisk reaktion.
tiredness), dizziness, somnolence (sleepiness), vomiting, diarrhoea, nausea, dyspepsia (indigestion), and increased blood levels of liver enzymes. uncommon (at least 1 in 1,000 patients): rash, hair loss. rare (at least 1 in 10,000 patients): severe allergic reaction.
træthed, søvnbesvær, angst, følelse af uro og mærkelige drømme
tiredness, trouble sleeping, anxiety, feeling agitated or having abnormal dreams
træthed, udmattelse
tiredness, exhaustion
Træthed, unormal eller kraftig blødning, som oftest fra næsen
Tiredness, abnormal or excessive bleeding commonly from the nose
Træthed, utilpashed
Fatigue, malaise
Træthed, utilpashed i brystet, varmefølelse, perifert ødem, smerter, brystsmerter, ansigtsødem, hypertermi
fatigue, chest discomfort, feeling hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia
Træthed, utilpashed, perifært ødem, seponeringssyndrom*
Fatigue, malaise peripheral oedema, withdrawal syndrome
Træthed, utilsigtede skader, hævelse i ansigtet, forhøjet blodtryk, diarré, flatulens, betændelsestilstand i mundslimhinden, forhøjede levertal, hævelser, svimmelhed, søvnløshed, døsighed, unormal tankegang, rindende næse, hoste, åndenød, tør hud, kløe, hududslæt, svedtendens, synsforstyrrelser inklusive sløret syn, smagsforstyrrelser, urinvejsforstyrrelser eller -infektion, impotens, udflåd og kløe i skeden, blæresmerter, besvær med at tømme blæren.
Fatigue, accidental injury, facial swelling, high blood pressure, diarrhoea, flatulence, inflammation of the mucous membrane of the mouth, increased liver enzymes, swelling, dizziness, sleeplessness, drowsiness, abnormal thinking, runny nose (rhinitis), cough, shortness of breath, dry skin, itching, rash, sweating, visual disturbance including blurred vision, taste disturbance, urinary tract disorder or infection, impotence, discharge and itching in the vagina, bladder pain, inability to empty your bladder.
Træthed, ødemer (herunder perifere ødemer), pyreksi, asteni, influenzalignende sygdom (herunder pyreksi, hoste, myalgi, muskuloskeletale smerter, hovedpine og kulderystelser) Almindelig
Fatigue, Oedema (including peripheral oedema), Pyrexia, Asthenia, Influenza like illness syndrome (including pyrexia, cough, myalgia, musculoskeletal pain, headache and rigors) Common
Træthed, ødemer (sædvanligvis perifere)
Fatigue, oedema (most commonly peripheral)
Træthed, øget tørst og/eller trang til at lade vandet oftere end normalt, da disse kan være tegn på en stigning i sukkerindholdet i blodet
Tiredness, increased thirst and/or a need to pass urine more frequently than usual, as these may be signs of an increase in the amount of sugar in your blood
Træthed- eller svaghedsfornemmelse
Feeling agitated or sleepy
Træthed- eller svaghedsfornemmelse
Feeling tired or weak
Træthed.
fatigue
Træthed.
Tiredness
Træthed.
Tiredness (fatigue).
Træthed.
Tiredness.
Træthed/asteni
Fatigue/Asthenia
Træthed/asteni (53,2 %) (G3/4: 7,7 %)
Fatigue/Asthenia (53.2%) (G3/4 : 7.7%)
træthed1,2
fatigue1, 2
Træthed2 Ikke almindelig
Fatigue2 Uncommon
træthed; feber.
fatigue; fever.
Trætheda
Fatiguea
Træthedam
Fatigueam
TræthedD, perifert ødemD
FatigueD, oedema peripheralD
træthedfølelse, døsighed eller søvnighed
tired feeling, drowsiness or sleepiness
Træthedj
Fatiguej
Træthedl
Fatiguel
trætheds- eller svaghedsfornemmelse
feeling tired or weak
Trætheds- eller svaghedsfølelse
Feeling tired or weak
Træthedsfornemmelse
Feeling tired
træthedsfornemmelse (somnolens)
feeling sleepy (somnolence)
træthedsfornemmelse, åndenød og hoste, der ikke forsvinder
feeling tired or short of breath, cough which will not go away
træthedsfølelse
feeling tired
træthedsfølelse eller voldsom tørst, øget appetit uden vægtøgning og hyppigere vandladning end vanligt – dette kan være tegn på øget blodsukkerniveau (hyperglykæmi).
feeling tired or very thirsty, having an increased appetite without gaining weight and passing more urine than usual – these may be signs of high level of sugar in the blood (hyperglycaemia).
træthedsfølelse unormale laboratorieprøver, herunder ændrede proteinniveauer i blodet, ændringer i blodfedt eller i leverenzymværdier eller høje niveauer af urinstof i blodet
feeling of tiredness abnormal laboratory tests including changes in protein levels in the blood, changes in blood fat or in liver enzyme values or high level of urea in the blood
trøske
oral candidiasis
Trøske (en svampeinfektion) i munden.
Thrush (a fungal infection) in the mouth.
trøske (svampeinfektion i munden), sår i næsen, næseblødning, forkølelsessår og betændelse i tungen. analyseværdier for leverfunktionen kan enten være forhøjede eller nedsatte under behandling med Caelyx.
oral thrush (a fungal infection in the mouth), sores in nose, bleeding from your nose, cold sores, and tongue inflammation; laboratory values related to the function of the liver may either increase or decrease while on Caelyx;
Trøske (vaginal svampeinfektion)
Thrush (vaginal yeast infection)
trøske i munden (oral candidiasis)
oral thrush (oral candidiasis)
TS-score
Total Sharp score
TSAT-ændring fra baseline på dag 35 (Mean ± SD, %)
TSAT change from Baseline at Day 35 (mean ± SD, %)
TSH >4 gange ULN efter start på behandling blev rapporteret hos 6,9 % af patienterne, der blev behandlet med Stivarga, og hos 0,7 % af patienterne, der fik placebo.
TSH post baseline >4 times ULN was reported in 6.9% of patients treated with Stivarga and in 0.7% of patients receiving placebo.
TSH-niveau skal være inden for normalområdet
TSH level must be within normal limits
TSST- en tilnærmelse af PFS2
TSST- an approximation of PFS2
TT-036 (11-17 år)
8222 (6807; 9930)
Ttager riociguat.
are taking riociguat.
TTP = Tid til progression CI = konfidensinterval
NA=not applicable, NE=not estimated TTP-Time to Progression CI=Confidence Interval
TTP = tid til progression.
1 prior line of therapy
TTP = tid til progression. "ne" indikerer at dette ikke kunne estimeres eller ikke blev nået.
TTP=time to progression; “ne” indicates that it could not be estimated or it was not yet reached.
TTP = tid til progression. ”ne” indikerer at dette ikke kunne estimeres eller ikke blev nået.
TTP = time to progression; “ne” indicates that it could not be estimated or it was not yet reached.
TTP er en potentielt dødeligtilstand, der kræver øjeblikkelig behandling, der omfatter plasmaferese.
TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.
TTP is een potentieel fatale aandoening die directe behandeling vereist, met inbegrip van plasmaferese.
TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.
TTP var signifikant længere hos patienter, der fik regorafenib plus BSC, end hos patienter, der fik placebo plus BSC, med en hazard ratio på 0,248 [95 % CI 0,170; 0,364], og en median TTP på 5,4 måneder versus 0,9 måneder (p<0,000001) (se tabel 7).
TTP was significantly longer in the patients receiving regorafenib plus BSC than in patients receiving placebo plus BSC with a hazard ratio of 0.248 [95% CI 0.170, 0.364], and median TTP of 5.4 months versus 0.9 months (p<0.000001) (see Table 7).
TTP wordt gekenmerkt door trombocytopenie en microangiopathische hemolytische anemie in combinatie met neurologische afwijkingen of nierdisfunctie of koorts.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
TTP, dage [95% CI]
TTP, days [95% CI]
TTP, måneder
Median duration Days (months)
TUabel 2U: Incidens af patienter med hoftefraktur og relativ risikoreduktion hos patienter med BMD ≤-2,4 SD (NHANES III) og  74 år
Table 2: Incidence of patients with hip fracture and relative risk reduction in patients with BMD ≤ -2.4 SD (NHANES III) and age ≥ 74 years
Tube (polyethylen)
Tube (polythylene)
TUBE 150 mikrog/g GEL
TUBE 150 mcg/g GEL
TUBE 500 mikrog/g GEL
TUBE 500 mcg/g GEL
Tube indeholdende 15 g creme
Tube containing 15 g of cream
tube: 10 mg terbinafin, 10 mg florfenicol, 1 mg betamethasonacetat
dose: 10 mg terbinafine, 10 mg florfenicol, 1 mg betamethasone acetate
Tuben skal lukkes omhyggeligt efter hver brug.
The tube should be closed tightly after each use.
Tubens indhold bør påføres et behandlingsareal på 25 cm2.
The content of the tube should be applied to one treatment area of 25 cm2.
TUBER
TUBES
Tuberkulintest: Røntgenundersøgelse af lunger:
Tuberculin test: Chest X-ray:
Tuberkulose (TB), har haft tuberkulose, eller hvis du har en anden lungeinfektion
Tuberculosis (TB) now or have had in the past, or have other lung infections
Tuberkulose er blevet rapporteret hos MF-patienter behandlet med Jakavi.
Tuberculosis has been reported in patients receiving Jakavi for MF.
Tuberkulose kan udvikles under behandlingen, også selv om du har fået behandling for at forebygge tuberkulose.
Tuberculosis can develop during therapy even if you have received treatment for the prevention of tuberculosis.
Tuberkulose og andre opportunistiske infektioner (infektioner, der optræder, når modstandsdygtigheden over for sygdommen er nedsat); lungesygdom.
tuberculosis and other opportunistic infections (infections that occur when resistance to disease is lowered); lung disease.
Tuberkulose, bakterieinfektioner, inklusive sepsis og pneumoni, invasive svampeinfektioner, virale infektioner og andre opportunistiske infektioner har væ ret observeret hos patienter, der fik infliximab.
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving infliximab.
Tuberkulose, svampeinfektioner (fx candidiasis).
Tuberculosis, fungal infections (e.g. candidiasis).
Tuberkulosee
Tuberculosise
tuberkuloseinfektion
tuberculosis infection
Tuberne skal kasseres efter at have været åbnet.
Tubes should be discarded after first opening.
Tubespidsen må ikke komme i kontakt med såret eller nogen anden overflade.
The tip of the tube should not come into contact with the wound or any other surface.
Tubulo- interstitiel nefritis
Tubulointerstitial nephritis
tubulointerstitiel nefritis
tubulointerstitial nephritis
tubulointerstitiel nefritis (shock-nyre), nyresvigt
tubulointerstitial nephritis, renal failure
tubulointerstitiel nefritis, nyresvigta,b
tubulointerstitial nephritis, renal failurea,b
Tubulær toksicitet blev også observeret i et 2-årigt oralt karcinogenicitetsstudie med mus ved doser på 25, 75 og 150 mg/kg/dag.
Tubular toxicity was also observed in a 2 year oral carcinogenicity study in mice at doses of 25, 75 and 150 mg/kg/day.
tudie (2006)
1.26 (0.95, 1.67)
tudierapporter –
Interim Study
tudiet Dag 3* (n=57)
Study Day 3* (n=57)
Tulathromycin er aktivt in vitro mod Mannheimia haemolytica, Pasteurella multocida, Histophilus somni og Mycoplasma bovis, samt mod Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis og Bordetella bronchiseptica de patogen bakterier, som oftest forårsager luftvejsinfektioner hos henholdsvis kvæg og svin.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulathromycin er aktivt in vitro mod Mannheimia haemolytica, Pasteurella multocida, Histophilus somni og Mycoplasma bovis, samt mod Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis og Bordetella bronchiseptica de patogene bakterier, som oftest forårsager luftvejsinfektioner hos henholdsvis kvæg og svin.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulathromycin er aktivt in vitro mod Mannheimia haemolytica, Pasteurella multocida, Histophilus somni og Mycoplasma bovis, samt mod Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis og Bordetella bronchiseptica de patogene bakterier, som oftest forårsager luftvejsinfektioner hos henholdsvis kvæg og svin.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumonia, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tumor blev vurderet ifølge RECIST.
Tumour assessments, according to the RECIST.
tumor i hypotalamus eller hypofyse
tumours of the hypothalamus or pituitary gland
tumor i hypotalamus eller hypofyse
tumours of the hypothalamus or pituitary gland;
Tumor lysis-syndrom – stofskiftekomplikationer, der kan forekomme i løbet af kræft- behandling og nogle gange endda uden behandling.
Tumour Lysis Syndrome - metabolic complications that can occur during the treatment of cancer and sometimes even without treatment.
Tumor nekrose faktor alfa (TNFα) frembringer betæ ndelse og modulerer cellulæ rt immunrespons.
Tumour necrosis factor alpha (TNFα) mediates inflammation and modulates cellular immune responses.
Tumor smerte
Tumour pain
Tumor-flare-reaktion kan ligne sygdomsprogression.
Tumour flare reaction may mimic progression of disease (PD).
Tumor-flare-reaktion, planocellulær hudcancerˆ◊, basalcellekarcinom ◊
Tumour flare reaction, Squamous skin cancerˆ◊, Basal cell Carcinoma◊
Tumor-lysis-syndrom (se også data fra programmet for udleveringstilladelse og fra de ikke pivotale-studier)
Tumour lysis syndrome (see also Data from compassionate use programme and non-pivotal studies)
Tumor-response rate (%)
Tumor response rate (%)
Tumor-response rate (%) 95 % CI
Number of patients Tumour response rate (%) 95% CI
Tumor-responsrate (%)
Tumour response rate
Tumor-responsrate (%)
Tumour response rate (%)
Tumor-responsrate (%) 95 % CI
Tumour response rate
Tumor-responsrate Relativ risiko (95 % C.I.)
Tumour response rate
Tumorblødning*
Tumour haemorrhage
Tumorblødning/tumornekrose*
Tumour haemorrhage/tumour necrosis
Tumorblødningera
Tumour bleedingsa
Tumorbyrde
Tumour burden
Tumorcelledød opstår også via iskæmisk nekrose sekundært til vaskulær okklusion, der viser sig at være delvist medieret af thromboxan A2- frigørelse.
Tumour cell death also occurs through ischaemic necrosis secondary to vascular occlusion that appears to be partly mediated by thromboxane A2 release.
Tumorer
Neoplasms
tumorer (inkl.
lymphatic system
Tumorer i hypotalamus eller hypofyse
Tumours of the hypothalamus or pituitary gland
Tumorer i hypotalamus eller hypofyse
Tumours of the hypothalamus orpituitary gland
tumorer i hypothalamus eller hypofysen
tumours of the hypothalamus and pituitary gland
Tumorer i ovarier, mammae, uterus, hypofysen eller hypotalamus.
Tumours of the ovary, breast, uterus, pituitary or hypothalamus.
Tumorer i ovarierne, mammae, uterus, testis, hypofysen eller hypothalamus.
Tumours of the ovary, breast, uterus, testis, pituitary or hypothalamus.
Tumorer i æggestokkene og andre forplantningsorganer
Ovarian and Other Reproductive System Tumours
Tumorer inden for 1 cm fra øjne, næse, mund, ører eller hårkant blev ikke inkluderet.
Tumours located within 1 cm of the eyes, nose, mouth, ears or hairline were excluded.
Tumorer med overekspression af HER2 (ErbB2) er karakteriseret ved IHC3+ eller IHC2+ med gen- amplifikation eller gen-amplifikation alene.
HER2 (ErbB2) overexpressing tumours are defined by IHC3+, or IHC2+ with gene amplification or gene amplification alone.
Tumorer skal være inaktive, og De skal have afsluttet Deres kræftbehandling, inden De starter behandling med NutropinAq. hvis De har komplikationer efter en større operation (åben hjerteoperation eller mave/tarmoperation), er svært kvæstet, har akut vejrtrækningssvigt eller lignende tilstande.
Tumours must be inactive and you must have finished your anti-tumour treatment before you start treatment with NutropinAq. if you have complications after a major surgery (open-heart or abdominal surgery), a multiple trauma, acute respiratory failure, or similar conditions.
Tumorer, der vides at erodere ind i et større blodkar på eller i umiddelbar nærhed af bestrålingsstedet
Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site.
Tumorevalueringer blev foretaget ifølge Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 i Studie A og RECIST 1.1 i Studie B.
Tumour evaluations were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 in Study A and RECIST 1.1 in Study B.
tumorlyse-
infusion-related
tumorlyse-
Rare
Tumorlyse- syndrom
tumour lysis syndrome
Tumorlysesyndro m
Tumour lysis syndrome
tumorlysesyndrom
Grade 3−4 ADRs/Frequency
Tumorlysesyndrom
Tumour lysis syndrome
Tumorlysesyndrom (TLS)
Tumour Lysis Syndrome (TLS)
Tumorlysesyndrom (TLS) – TLS består af forskellige metaboliske komplikationer, som kan opstå under behandling af kræft.
Tumour lysis syndrome (TLS) – TLS consists of a group of metabolic complications that can occur during treatment of cancer.
Tumorlysesyndrom (TLS): Der er forekommet tilfælde af unormale niveauer i blodet af stoffer fra tumorhenfald, forårsaget af den hurtige nedbrydning af kræftceller under behandling af kræft og i visse tilfælde endda uden behandling.
Tumour lysis syndrome (TLS): Unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have happened during treatment of cancer and sometimes even without treatment.
Tumorlysesyndrom Hyperurikæmi
Epistaxis Petechiae
Tumorlysesyndrom – metaboliske komplikationer, der kan forekomme under cancerbehandling og nogle gange endda uden behandling.
Tumour lysis syndrome - Metabolic complications that can occur during treatment of cancer and sometimes even without treatment.
Tumorlysesyndrom*
Tumour lysis syndrome
tumorlysesyndrom, dehydrering, hypoalbuminæmi, hyperkolesterolæmi
tumour lysis syndrome, dehydration, hypoalbuminemia, hypercholesterolemia
Tumorlysesyndrom, hyperuricæmi
Tumour lysis syndrome, hyperuricaemia
Tumorlysesyndrom, manglende trivsel*, hypomagnesiæmi*, hypofosfatæmi*, hyperkaliæmi*, hypercalcæmi *, hypernatriæmi*, anormal urinsyre*, diabetes mellitus*, væskeretention
Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention
Tumorlysesyndrom, manglende trivsel*, hypomagnesiæmi*, hypofosfatæmi*, hyperkaliæmi*, hyperkalcæmi *, hypernatriæmi*, unormal urinsyre*, diabetes mellitus*, væskeretention
Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention
Tumornekrosefaktor (TNF)-hæmmere (som etanercept, adalimumbab eller infliximab), der primært anvendes til reumatisk og autoimmun sygdom.
Medicines called Tumour Necrosis Factor (TNF) inhibitors (such as etanercept, adalimumab, or infliximab) predominantly used in rheumatoid and autoimmune disease.
Tumorreduktion [%]°
Tumour shrinkage [%]°
Tumorrespons blev vurderet hver 12. uge.
Tumour response was assessed at 12-week intervals.
Tumorrespons blev vurderet i henhold til de reviderede NHL-kriterier (non-Hodgkins lymfom) fra International Working Group (IWG).
Tumour response was assessed according to the revised International Working Group (IWG) for non-Hodgkin’s lymphoma (NHL) criteria.
Tumorrespons øges hos patienter med fuldt belyste læsioner med en dybde på 10mm eller mindre.
Tumour responses are enhanced in patients with fully illuminated lesions of
Tumorresponsrate (%)
Tumor response rate (%)
Tumorsmerte
Tumour pain
tumorsmerter
tumour pain
tumorsmerter, hedeture, utilpashed, kuldesyndrom,
tumour pain, flushing, malaise, cold syndrome,
Tumorsmerter, inficeret neoplasme
Tumour pain, Infected neoplasm
Tumorsmerter, inficeret tumor
Tumour pain, infected tumour
Tumorsmerter, Myelodysplastisk syndrom/akut myeloid leukæmi*,
Tumour pain, Myelodysplastic syndrome/Acute myeloid leukaemia
Tumorstørrelse
Tumour size
Tumorstørrelse blev ikke målt direkte under det kliniske forsøg, men der sås et indirekte fordelagtigt tumorrespons med degarelix som vist med en 95% reduktion efter 12 måneder i median PSA.
Tumour size was not measured directly during the clinical trial programme, but there was an indirect beneficial tumour response as shown by a 95% reduction after 12 months in median PSA for degarelix.
Tumorudviklingen blev forudgået af pneumocytproliferation i lungen, som ikke observeredes hos rotter, hunde eller aber, hvilket tyder på at nøglehændelsen i udviklingen af lungetumorer hos mus sandsynligvis er artsspecifik.
Tumour development was preceded by pneumocyte proliferation in the lung which was not observed in rats, dogs, or monkeys, indicating that a key event in lung tumour development observed in mice likely was species-specific.
Tumorvurderinger fortsatte efter seponering hos patienter, hvor behandlingen blev seponeret af andre årsager end progression.
Tumour assessments were continued after treatment discontinuation in patients who discontinued treatment for reasons other than progression.
Tumour størrelse
Tumour size
tungen eller læberne er blå
blueness of the tongue or lips
tungeødem, ansigtsødem
tongue oedema, face oedema
TUP’er = tidligere ubehandlede patienter TBP’er = tidligere behandlede patienter MBP’er = minimalt behandlede patienter
PUPs = previously untreated patients PTPs = previously treated patients MTPs = minimally treated patients
Turbospin er en tørpulverinhalator drevet af det inspiratoriske flow og fremstillet af polypropylen og rustfrit stål.
The Turbospin is an inspiratory flow driven dry powder inhaler made of polypropylene and stainless steel.
Turbospin-enheden skal bortskaffes efter færdiggørelse af en behandlingspakke.
The Turbospin device should be discarded after completion of the treatment pack.
Turbospin-inhalatoren skal rengøres efter hver dosis ved at følge nedenstående fremgangsmåde:
Clean the Turbospin inhaler after each dose using the following procedure:
Turkis
Teal
Turners syndrom er en genetisk sygdom hos piger, der kan påvirke din vækst – din læge vil have fortalt dig, hvis du lider af det.
Turner syndrome is a genetic disorder in girls that can affect growth – your doctor will have told you if you have this.
Turner’s syndrom
Turner syndrome
Turnhoutseweg 30 B-2340 Beerse Belgien
Turnhoutseweg, 30 B-2340 Beerse Belgium
Turnhoutseweg 30, B-2340 Beerse Belgien
Turnhoutseweg, 30 B-2340 Beerse Belgium
Turnhoutseweg, 30 B-2340 Beerse Belgien
Turnhoutseweg, 30 B-2340 Beerse Belgium
turoctocog alfa (human koagulations faktor VIII (rDNA))
turoctocog alfa (human coagulation factor VIII (rDNA))
Turoctocog alfa (human koagulationsfaktor VIII (rDNA)) er et oprenset protein der har 1.445 aminosyrer og en molekylevægt på cirka 166 kDA.
Turoctocog alfa (human coagulation factor VIII (rDNA) is a purified protein that has 1,445 amino acids with an approximate molecular mass of 166 kDA.
Turoctocog alfa er en B-domæne trunkeret rekombinant human koagulationsfaktor VIII (B-domænet består af 21 aminosyrer fra vildtype B-domænet) uden nogen andre modifikationer i aminosyresekvensen.
Turoctocog alfa is a B-domain truncated recombinant human coagulation factor VIII (B-domain consists of 21 amino acids of the wild type B-domain) without any other modificationsin the amino acid sequence.